AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant
With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.
You may also be interested in...
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.